Merus Acquires License for Halozyme Therapeutics' ENHANZE Drug Delivery Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 17 2025
0mins
Source: NASDAQ.COM
Collaboration Agreement: Merus N.V. has entered a global non-exclusive collaboration and license agreement with Halozyme Therapeutics for the ENHANZE drug delivery technology.
Product Development: The agreement allows Merus to develop and potentially commercialize subcutaneous administration of petosemtamab, which shows promise in treating various solid tumor cancers, particularly head and neck cancer.
Financial Terms: Merus will make an upfront payment to Halozyme and may incur future milestone payments based on commercial success, along with royalties on net sales of the product.
Market Update: As of November 14, Merus N.V. shares closed at $95.95, reflecting a slight decrease of 0.14% on the Nasdaq.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
